The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
Open accessAbstract
Homeobox (HOX) proteins and the receptor tyrosine kinase FLT3 are frequently highly expressed and mutated in acute myeloid leukemia (AML). Aberrant HOX expression is found in nearly all AMLs that harbor a mutation in the Nucleophosmin (NPM1) gene, and FLT3 is concomitantly mutated in approximately 60% of these cases. Little is known about how mutant NPM1 (NPM1mut) cells maintain aberrant gene expression. Here, we demonstrate that the histone modifiers MLL1 and DOT1L control HOX and FLT3 expression and differentiation in NPM1mut AML. Using a CRISPR/Cas9 genome editing domain screen, we show NPM1mut AML to be exceptionally dependent on the menin binding site in MLL1. Pharmacologic small-molecule inhibition of the menin–MLL1 protein interaction had profound antileukemic activity in human and murine models of NPM1mut AML. Combined pharmacologic inhibition of menin–MLL1 and DOT1L resulted in dramatic suppression of HOX and FLT3 expression, induction of differentiation, and superior activity against NPM1mut leukemia. Significance: MLL1 and DOT1L are chromatin regulators that control HOX, MEIS1, and FLT3 expression and are therapeutic targets in NPM1mut AML. Combinatorial small-molecule inhibition has synergistic on-target activity and constitutes a novel therapeutic concept for this common AML subtype. Cancer Discov; 6(10); 1166–81. ©2016 AACR. See related commentary by Hourigan and Aplan, p. 1087. This article is highlighted in the In This Issue feature, p. 1069
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×
“MLL1-rearranged leukemias exhibit aberrant HOXA-cluster expression as a consequence of chromatin binding of the MLL1fusion complex(18), which in turn requires the association with at least two other proteins, menin and LEDGF.”
BackgroundSelf-citationMLL translocations, histone modifications and leukaemia stem-cell development
Krivtsov, A. V., & Armstrong, S. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2253 · Cited by 1,249
Self-citationSelective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923
Self-citationAltered Hox expression and segmental identity in Mll-mutant mice
Yu, B. D., Hess, J. L., Horning, S. E., Brown, G. A. J., & Korsmeyer, S. J. (1995) · Nature · doi:10.1038/378505a0 · Cited by 875
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870
Self-citationAssessment of Minimal Residual Disease in Standard-Risk AML
Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., Patel, Y., Bhudia, N., Farah, H., Mason, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507471 · Cited by 845
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Shi, J., Wang, E., Milazzo, J. P., Wang, Z., Kinney, J. B., & Vakoc, C. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3235 · Cited by 761
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M. F., Haferlach, T., Hiddemann, W., & Falini, B. (2005) · Blood · doi:10.1182/blood-2005-06-2248 · Cited by 713
Yokoyama, A., Somervaille, T. C. P., Smith, K. S., Rozenblatt-Rosen, O., Meyerson, M., & Cleary, M. L. (2005) · Cell · doi:10.1016/j.cell.2005.09.025 · Cited by 688
Verhaak, R. G. W., Goudswaard, C. S., van Putten, W., Bijl, M. A., Sanders, M. A., Hugens, W., Uitterlinden, A. G., Erpelinck, C. A. J., Delwel, R., Löwenberg, B., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2168 · Cited by 618
Revisiting Global Gene Expression Analysis
Lovén, J., Orlando, D. A., Sigova, A. A., Lin, C. Y., Rahl, P. B., Burge, C. B., Levens, D. L., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.10.012 · Cited by 616
Menin Critically Links MLL Proteins with LEDGF on Cancer-Associated Target Genes
Yokoyama, A., & Cleary, M. L. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.003 · Cited by 555
Sauvageau, G., Lansdorp, P. M., Eaves, C. J., Hogge, D. E., Dragowska, W. H., Reid, D. S., Largman, C., Lawrence, H. J., & Humphries, R. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12223 · Cited by 497
Hox genes in hematopoiesis and leukemogenesis
Argiropoulos, B., & Humphries, R. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210760 · Cited by 492 · cited 3×
“Specific members of the HOXA- and HOXB-cluster are required to maintain self-renewal properties of hematopoietic stem cells (HSCs)(3).”
BackgroundMenin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A. G., Sorenson, R. J., Showalter, H. D., Murai, M. J., Belcher, A. M., Hartley, T., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.773 · Cited by 462
Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
Borkin, D., He, S., Miao, H., Kempinska, K., Pollock, J., Chase, J., Purohit, T., Malik, B., Zhao, T., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.016 · Cited by 392
Alcalay, M., Tiacci, E., Bergomas, R., Bigerna, B., Venturini, E., Minardi, S. P., Meani, N., Diverio, D., Bernard, L., Tizzoni, L., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0560 · Cited by 357
The role of HOX genes in normal hematopoiesis and acute leukemia
Alharbi, R. A., Pettengell, R., Pandha, H. S., & Morgan, R. (2013) · Leukemia · doi:10.1038/leu.2012.356 · Cited by 335
The same pocket in menin binds both MLL and JUND but has opposite effects on transcription
Huang, J., Gurung, B., Wan, B., Matkar, S., Veniaminova, N. A., Wan, K., Merchant, J. L., Hua, X., & Lei, M. (2012) · Nature · doi:10.1038/nature10806 · Cited by 310
Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone
Okuwaki, M., Matsumoto, K., Tsujimoto, M., & Nagata, K. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02939-8 · Cited by 267
Definitive Hematopoiesis Requires the Mixed-Lineage Leukemia Gene
Ernst, P., Fisher, J. K., Avery, W., Wade, S., Foy, D., & Korsmeyer, S. J. (2004) · Developmental Cell · doi:10.1016/s1534-5807(04)00061-9 · Cited by 265
Identification and Characterization of the Human Set1B Histone H3-Lys4 Methyltransferase Complex
Lee, J.-H., Tate, C. M., You, J.-S., & Skalnik, D. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609809200 · Cited by 263
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
Ribeiro, A. F. T., Pratcorona, M., Erpelinck-Verschueren, C., Rockova, V., Sanders, M., Abbas, S., Figueroa, M. E., Zeilemaker, A., Melnick, A., Löwenberg, B., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367961 · Cited by 262
Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice
Vassiliou, G. S., Cooper, J. L., Rad, R., Li, J., Rice, S., Uren, A., Rad, L., Ellis, P., Andrews, R., Banerjee, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.796 · Cited by 233
Self-citationChen, C.-W., Koche, R. P., Sinha, A. U., Deshpande, A. J., Zhu, N., Eng, R., Doench, J. G., Xu, H., Chu, S. H., Qi, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3832 · Cited by 228
Self-citationShi, A., Murai, M. J., He, S., Lund, G., Hartley, T., Purohit, T., Reddy, G., Chruszcz, M., Grembecka, J., & Cierpicki, T. (2012) · Blood · doi:10.1182/blood-2012-05-429274 · Cited by 204
Mullighan, C. G., Kennedy, A., Zhou, X., Radtke, I., Phillips, L. A., Shurtleff, S. A., & Downing, J. R. (2007) · Leukemia · doi:10.1038/sj.leu.2404808 · Cited by 180
Gaidzik, V. I., Schlenk, R. F., Paschka, P., Stölzle, A., Späth, D., Kuendgen, A., von Lilienfeld-Toal, M., Brugger, W., Derigs, H. G., Kremers, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461624 · Cited by 177
Chen, Y.-X., Yan, J., Keeshan, K., Tubbs, A. T., Wang, H., Silva, A., Brown, E. J., Hess, J. L., Pear, W. S., & Hua, X. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510347103 · Cited by 175
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l
Deshpande, A. J., Chen, L., Fazio, M., Sinha, A. U., Bernt, K. M., Banka, D., Dias, S., Chang, J., Olhava, E. J., Daigle, S. R., et al. (2013) · Blood · doi:10.1182/blood-2012-11-465120 · Cited by 174
Self-citationAF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes
Deshpande, A. J., Deshpande, A., Sinha, A. U., Chen, L., Chang, J., Cihan, A., Fazio, M., Chen, C.-W., Zhu, N., Koche, R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.009 · Cited by 174
Self-citationStructure of the MLL CXXC domain–DNA complex and its functional role in MLL-AF9 leukemia
Cierpicki, T., Risner, L. E., Grembecka, J., Lukasik, S. M., Popovic, R., Omonkowska, M., Shultis, D. D., Zeleznik-Le, N. J., & Bushweller, J. H. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1714 · Cited by 172
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 170
The Histone Methyltransferase Activity of MLL1 Is Dispensable for Hematopoiesis and Leukemogenesis
Mishra, B. P., Zaffuto, K. M., Artinger, E. L., Org, T., Mikkola, H. K. A., Cheng, C., Djabali, M., & Ernst, P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.015 · Cited by 151
Giampaolo, A., Sterpetti, P., Bulgarini, D., Samoggia, P., Pelosi, E., Valtieri, M., & Peschle, C. (1994) · Blood · doi:10.1182/blood.v84.11.3637.bloodjournal84113637 · Cited by 145
Klaus, C. R., Iwanowicz, D., Johnston, D., Campbell, C. T., Smith, J. J., Moyer, M. P., Copeland, R. A., Olhava, E. J., Scott, M. P., Pollock, R. M., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214577 · Cited by 137
Ostronoff, F., Othus, M. K. D., Lazenby, M., Estey, E. H., Appelbaum, F. R., Evans, A., Godwin, J. E., Gilkes, A., Kopecky, K. J., Burnett, A. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0571 · Cited by 137
Spencer, D. H., Young, M. A., Lamprecht, T. L., Helton, N., Fulton, R. S., O’Laughlin, M. D., Fronick, C. C., Magrini, V. J., Demeter, R., Miller, C. A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.6 · Cited by 134
Wang, G. G., Pasillas, M. P., & Kamps, M. P. (2005) · Blood · doi:10.1182/blood-2004-12-4664 · Cited by 123
Nucleophosmin mutations in acute myeloid leukemia: A tale of protein unfolding and mislocalization
Federici, L., & Falini, B. (2013) · Protein Science · doi:10.1002/pro.2240 · Cited by 116
Mupo, A., Celani, L., Dovey, O. M., Cooper, J. L., Grove, C. S., Rad, R., Sportoletti, P., Falini, B., Bradley, A., & Vassiliou, G. S. (2013) · Leukemia · doi:10.1038/leu.2013.77 · Cited by 90
Self-citationDactinomycin in NPM1-Mutated Acute Myeloid Leukemia
Falini, B., Brunetti, L., & Martelli, M. P. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1509584 · Cited by 74
Mixed lineage rearranged leukaemia
Stein, E. M., & Tallman, M. S. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000123 · Cited by 69
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia
Deshpande, A. J., Bradner, J. E., & Armstrong, S. A. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.06.002 · Cited by 63
Self-citationMLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition
Kühn, M. W. M., Hadler, M., Daigle, S. R., Koche, R. P., Krivtsov, A. V., Olhava, E. J., Caligiuri, M. A., Huang, G., Bradner, J. E., Pollock, R. M., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.115337 · Cited by 54
Self-citationNovotny, E. A., Compton, S. T., Liu, P. P., Collins, F. S., & Chandrasekharappa, S. C. (2009) · Mechanisms of Development · doi:10.1016/j.mod.2009.04.001 · Cited by 12
Cited by
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Issa, G. C., Aldoss, I., DiPersio, J., Cuglievan, B., Stone, R., Arellano, M., Thirman, M. J., Patel, M. R., Dickens, D. S., Shenoy, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05812-3 · Cited by 507
Self-citationKrivtsov, A. V., Evans, K., Gadrey, J. Y., Eschle, B. K., Hatton, C., Uckelmann, H. J., Ross, K. N., Perner, F., Olsen, S. N., Pritchard, T., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.001 · Cited by 447
Self-citationTargeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 413
NPM1-mutated acute myeloid leukemia: from bench to bedside
Falini, B., Brunetti, L., Sportoletti, P., & Martelli, M. P. (2020) · Blood · doi:10.1182/blood.2019004226 · Cited by 337
Mutant NPM1 Maintains the Leukemic State through HOX Expression
Brunetti, L., Gundry, M. C., Sorcini, D., Guzman, A. G., Huang, Y.-H., Ramabadran, R., Gionfriddo, I., Mezzasoma, F., Milano, F., Nabet, B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.005 · Cited by 313
Metadata
- Authors
- Kühn, M. W. M., Song, E., Feng, Z., Sinha, A., Chen, C.-W., Deshpande, A. J., Cusan, M., Farnoud, N., Mupo, A., Grove, C., Koche, R., Bradner, J. E., de Stanchina, E., Vassiliou, G. S., Hoshii, T., & Armstrong, S. A.
- Venue
- Cancer Discovery
- Published
- 2016-10-01
- Volume
- 6
- Issue
- 10
- Pages
- 1166-1181
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4241093998
- Cited by
- 264
- References
- 50
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.